Dr. Ridolfi Laura obtained her medical degree at the University of Bologna, postgraduate specialization at Medical Oncology at the University of Ferrara, and her PhD in Immunology and Cellular Biology at the University of Turin. She has twenty years of experience as the Principal Investigator and Sub-Investigator of phase I–III International clinical trials, and won a Grant from “Ricerca Finalizzata 2009- Ministero della Salute – Direzione Generale della Ricerca Scientifica e Tecnologica” for a study on the treatment of melanoma and renal cell carcinoma with high-dose IL2 plus radiotherapy. Since January 2018, she has been a member of the Ethics Commitee AVEN (Area Vasta Emilia Nord). Since October 2022, she has been the Medical Director of the Somatic Cell Therapy Unit in solid tumors and the Coordinator of clinical and preclinical research in the field of rare tumors and the development of new cellular product at IRST “Dino Amadori”. She is a funding member of NOTA (Network Officine Terapie Avanzate APS), a non-profit network of Italian authorized cell factories, and Regional Coordinator of Women for Oncology—Italy.